Table 1.
Clinical features of patients with antibodies in the cerebrospinal fluid, and comparison between those with concordant and discordant results.
| Concordant in-house/commercial IIFA | Discordant in-house/commercial IIFA | p value | |
|---|---|---|---|
| LGI1+ | 27 (19 [A] + 8 [B]) | 10 (6 [A] + 4 [B]) | |
| Median age | 65 y (range: 43-88) | 59 y (range: 36-83) | 0.352 |
| Male sex | 15 (55%) | 5 (50%) | 1.00 |
| Encephalitis | 23 (85%) *3 seizures, 1 Morvan’s syndrome | 10 (100%) | 0.557 |
| Abnormal MRI | 11/16 (69%) | 4/6 (67%) | 1.00 |
| Tumor | 2 (7%) **1 breast cancer, 1 thymoma | 1 (10%) **1 colon adenocarcinoma | 1.00 |
| GABABR+ | 21 (5 [A] + 16 [B]) | 11 (4 [A] + 7 [B]) | |
| Median age | 63.5 y (range: 24-78) | 57 y (range: 36-81) | 0.942 |
| Male sex | 12 (57%) | 5 (45%) | 0.712 |
| Encephalitis | 20 (95%) *1 refractory seizures | 6 (55%) *4 refractory seizures, 1 chorea | 0.011 |
| Abnormal MRI | 11/16 (69%) | 2/9 (22%) | 0.041 |
| Tumor | 9 (43%) **5 lung cancer, 2 neuroendocrine of unknown origin, 1 gastric, 1 vesical | 4 (36%) ** 3 lung, 1 breast cancer | 1.00 |
| AMPAR+ | 18 (4 [A] + 14 [B]) | 7 (2[A] + 5[B]) | |
| Median age | 58 y (range: 21-83) | 54 y (range: 27-81) | 0.981 |
| Male sex | 9 (50%) | 3 (43%) | 1.00 |
| Encephalitis | 17 (94%) *1 refractory seizures | 6 (86%) *1 refractory seizures | 0.490 |
| Abnormal MRI | 10/12 (83%) | 1/5 (20%) | 0.028 |
| Tumor | 11 (61%) **5 lung cancer, 4 thymoma, 1 breast, 1 teratoma | 4 (57%) **3 lung cancer, 1 teratoma | 1.00 |
A, patients from Cohort A; B, patients from Cohort B; IIFA, indirect immunofluorescence assay; MRI, magnetic resonance image; y, years.
*Other clinical presentations; **Tumor types.
In bold: Statistical significance p < 0.05.